Ascletis Receives FDA Clearance to Advance ASC50, a Novel Oral IL-17 Inhibitor, Into ...

Retrieved on: 2025-05-22 13:59:17

Tags for this article:

Click the tags to see associated articles and topics

Ascletis Receives FDA Clearance to Advance ASC50, a Novel Oral IL-17 Inhibitor, Into .... View article details on hiswai:

Excerpt

While IL-17 is already a well-established therapeutic target, with several monoclonal antibodies against IL-17 or its receptor (ixekizumab, ...

Article found on: www.dermatologytimes.com